Investor Relations - GSK and Theravance announce progression of LAMA/LABA combination treatment into Phase III development for COPD; Relovair(TM ) programme expanded by start of large Phase IIIb COPD outcomes study

GSK and Theravance announce progression of LAMA/LABA combination treatment into Phase III development for COPD; Relovair(TM ) programme expanded by start of large Phase IIIb COPD outcomes study

Feb 03, 2011

Supporting Materials:

GSK THRX LAMA LABA Combo and RELOVAIR Outcomes Phase 3 Studies Press Release 2011Feb3 FINAL.pdf 329.4 KB

GSK and Theravance announce progression of LAMA/LABA combination treatment into Phase III development for COPD; Relovair<font size="-1"><sup></sup></font> programme expanded by start of large Phase IIIb COPD outcomes study